Xencor Stock Price, News & Analysis

Xencor, a clinical-stage biopharmaceutical company, reported significant financial results for Q2 2021, with total revenue soaring to $67.4 million, up from $13.1 million year-on-year. The company initiated a Phase 2 study for XmAb717 in metastatic prostate cancer and plans further studies for other drug candidates. R&D expenses increased to $49.5 million, reflecting ongoing development efforts. Xencor achieved a net income of $52.2 million, a turnaround from a net loss of $35 million in Q2 2020. The company aims to maintain cash reserves between $475 million and $500 million by year-end.

Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.

• Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
• Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
• BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
• Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
• Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.

A webcast of the Canaccord presentation will be available on Xencor's website.

Xencor, Inc. (NASDAQ: XNCR) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. The live call can be accessed via phone or a webcast on the company's website. Xencor is a clinical-stage biopharmaceutical firm focusing on engineered monoclonal antibodies and cytokines targeting cancer and autoimmune diseases, with 22 candidates in clinical development leveraging its XmAb® technology.

Xencor, Inc. (NASDAQ: XNCR) announced that Dr. Bassil Dahiyat, president and CEO, will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 p.m. ET. The presentation will cover Xencor's focus on developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases. A webcast of the event will be available on the company's website, with a replay accessible for at least 30 days following the event.

Xencor, Inc. (NASDAQ: XNCR) announced that the FDA has granted emergency use authorization for sotrovimab, an engineered monoclonal antibody developed with Vir Biotechnology and GlaxoSmithKline to treat mild-to-moderate COVID-19 in high-risk patients. While not approved, sotrovimab shows an 85% reduction in hospitalization or death based on Phase 3 trial data. Xencor has licensed its Xtend technology to Vir to enhance antibody performance. The EUA will last as long as the COVID-19 emergency declaration is in effect.

Xencor, a clinical-stage biopharmaceutical company (NASDAQ:XNCR), entered a licensing agreement with Bristol-Myers Squibb (NYSE:BMY) for its Xtend™ Fc technology to extend the half-life of the SARS-CoV-2 mAb Duo, designed for COVID-19 treatment. This antibody combination, discovered at Rockefeller University, is currently in Phase 1 clinical evaluation. Xencor, eligible for royalties from sales, emphasizes that its technology improves therapeutic performance, potentially lowering costs for antiviral therapies. The partnership aims to address urgent medical needs, particularly in the pandemic context.

Xencor, a clinical-stage biopharmaceutical company focusing on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, announced that its CEO, Bassil Dahiyat, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference. The event is set for May 19, 2021, at 1:20 p.m. ET. Investors can access a live webcast on the company's website, with a replay available for 30 days afterward. Xencor has 21 clinical candidates utilizing its XmAb technology.

Xencor, a clinical-stage biopharmaceutical company, reported Q1 2021 financial results, achieving a total revenue of $34 million, an increase from $32.4 million in Q1 2020. The net loss narrowed to $2.5 million or $(0.04) per share, compared to a loss of $8.1 million the previous year. Cash and equivalents amounted to $577.1 million. Recently, Xencor initiated a Phase 1 study for XmAb564 and presented preclinical data at the AACR meeting. Future clinical studies are planned for XmAb717 and Tidutamab.

Xencor, Inc. (NASDAQ: XNCR) has initiated a Phase 1 clinical study for XmAb564, targeting autoimmune diseases. The first subject has been dosed in this randomized, double-blind, placebo-controlled trial, which evaluates the safety and tolerability of XmAb564 in healthy volunteers. XmAb564 is designed to selectively activate regulatory T cells while minimizing activation of other immune cells, aimed at improving therapeutic outcomes. Preliminary studies indicate it has favorable pharmacologic properties and promotes sustained Treg proliferation.